Telesis Bio Inc TBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TBIO is a good fit for your portfolio.
News
-
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
-
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
-
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
-
Thinking about buying stock in Telesis Bio, Sellas Life Sciences, Mitek Systems, Monopar Therapeutics, or Inpixon?
Trading Information
- Previous Close Price
- $0.32
- Day Range
- $0.30–0.35
- 52-Week Range
- $0.30–3.01
- Bid/Ask
- $0.33 / $0.35
- Market Cap
- $10.51 Mil
- Volume/Avg
- 123,582 / 836,301
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents and BioXp biofoundry services.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.telesisbio.com
Valuation
|
Metric
|
TBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 41.81 |
Price/Sales | 0.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TBIO
|
|---|---|
Quick Ratio | 3.07 |
Current Ratio | 3.71 |
Interest Coverage | −14.92 |
Quick Ratio
TBIO
Profitability
|
Metric
|
TBIO
|
|---|---|
Return on Assets (Normalized) | −36.01% |
Return on Equity (Normalized) | −128.44% |
Return on Invested Capital (Normalized) | −38.95% |
Return on Assets
TBIO
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Vthxfhnwc | Tnsxyb | $185.8 Bil | |
SYK
| Stryker Corp | Vvwvqcmmw | Gxrvt | $127.4 Bil | |
MDT
| Medtronic PLC | Kwjqtdpff | Gztgpzs | $105.2 Bil | |
BSX
| Boston Scientific Corp | Wwsztxzxz | Nnqcmw | $99.0 Bil | |
DXCM
| DexCom Inc | Ghzgzhptw | Shjrz | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Grlrrhdv | Ljqxm | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Rkctdjkjc | Xyxr | $25.0 Bil | |
ALGN
| Align Technology Inc | Yqqdbptvp | Qgsvfc | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Pntvqcc | Fbbqky | $18.9 Bil | |
PODD
| Insulet Corp | Hfxvgghkqj | Qpsccb | $11.7 Bil |